amiodarone-colchicine |
1* |
Increased colchicine plasma concentrations
and increased risk of colchicine toxicity |
Inhibition of
P-glycoprotein-mediated colchicine efflux transport |
amiodarone-digoxin |
4* |
Digoxin toxicity (nausea, vomiting, cardiac
arrhythmias) and potentiated effects of amiodarone |
Inhibition of
p-glycoprotein by amiodarone, and reduction of digoxin clearance;
interference with amiodarone by digoxin |
amiodarone-fluconazole |
8* |
Increased amiodarone exposure and an
increased risk of cardiotoxicity |
Inhibition of CYP3A4-mediated
amiodarone-metabolism; additive QT-interval prolongation |
amiodarone-rifampin |
3* |
Decreased efficacy of amiodarone |
CYP450-mediated induction of amiodarone metabolism |
amiodarone-warfarin |
15* |
Increased risk of bleeding |
Increased
exposure to warfarin |
clopidogrel-omeprazole |
12* |
Reduced plasma concentrations of
clopidogrel active metabolite and reduced antiplatelet activity |
Inhibition of CYP2C19-mediated clopidogrel metabolism to active
metabolite by omeprazole |
fluconazole-tacrolimus |
2* |
Increased tacrolimus exposure and risk of
tacrolimus toxicity, including QT-interval prolongation |
Inhibition of
CYP3A4-mediated tacrolimus metabolism by fluconazole; additive effects
on QT-interval prolongation |
fluconazole-warfarin |
6* |
Increased risk of bleeding |
Disruption of
vitamin K synthesis; inhibition of CYP3A4-mediated warfarin
metabolism |
isosorbide-sildenafil |
1* |
Potentiation of hypotensive effects |
Increased levels of cyclic guanosine monophosphate from sildenafil and
nitrates |
amiodarone-simvastatin |
3 |
Increased exposure to simvastatin and an
increased risk of myopathy or rhabdomyolysis |
Inhibition by amiodarone
of CYP3A4-mediated simvastatin metabolism |
amlodipine-simvastatin |
1 |
Increased simvastatin exposure and
increased risk of myopathy, including rhabdomyolysis |
Unknown |
atorvastatin-colchicine |
1 |
Increased colchicine exposure; an
increased risk of myopathy or rhabdomyolysis |
Inhibition of hepatic and
renal p- glycoprotein mediated colchicine transport by atorvastatin;
unknown |
atorvastatin-diltiazem |
1 |
Increased risk of rhabdomyolysis |
Inhibition by diltiazem of cytochrome P450 3A4-mediated atorvastatin
metabolism |
esomeprazole-tacrolimus |
1 |
Increased tacrolimus exposure |
Inhibition
of CYP3A4-mediated tacrolimus metabolism by esomeprazole |
lamotrigine-primidone |
1 |
Decreased lamotrigine efficacy |
Hepatic
induction of lamotrigine metabolism |
metronidazole-warfarin |
1 |
Increased risk of bleeding |
Potentiation
of anticoagulation; prolonged prothrombin time |
omeprazole-tacrolimus |
5 |
Increased tacrolimus exposure |
Inhibition
of CYP3A4-mediated tacrolimus metabolism by omeprazole |